Yale Study: Vaccine Won’t End Virus On Its Own


Both Pfizer and Moderna say their COVID-19 vaccines are more than 90 percent effective. But a new study from the Yale School of Public Health says it’ll take more than a vaccine alone to end the virus.

Officials say a vaccine could start to be given to some vulnerable groups as soon as the end of the year. Jason Schwartz is with the Yale School of Public Health.

“We may not be at the beginning of the end, but we’re at the end of the beginning, as Winston Churchill said,” Schwartz said.

Schwartz and his team looked at other factors that’ll have to fall into place for the vaccine to be successful. He said manufacturing and delivering the vaccine will be as big a challenge as developing it.

“To get these vaccines produced at tens and hundreds of millions of doses, to deliver it to states, for states to allocate those vaccines to their communities, and to create the program to actually get it into people’s arms,” he said.

Schwartz said officials also need to educate the public about the vaccines’ importance and address skepticism about their safety.

“We know that there are chronic anxieties and fears about vaccines, and we know that there are specific concerns about this vaccine. Perhaps fears about how quickly it was developed or that corners were cut.”

Schwartz says officials can help by assuring people they’re confident in the vaccine — and they’ll be monitoring its safety after it’s been administered. And even after a vaccine is available, he says we’ll still have to wear masks and social distance for some time.



News Read More: Yale Study: Vaccine Won’t End Virus On Its Own

Get real time updates directly on you device, subscribe now.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.